Evidence map›Paper›PMID 29042795›Full record

ArticleOncoTargets and therapy2017

Significant association of the

Tingyan Shi, Rong Jiang, Pan Wang, Yuan Xu, Sheng Yin, Xi Cheng, Rongyu Zang

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Journal of Cancer · 2020
    Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Tingyan ShiDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University.
Rong JiangDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University.
Pan WangDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University.
Yuan XuCancer Institute.
Sheng YinDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University.
Xi ChengGynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Rongyu ZangDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University.
Gynecologic Oncology Group · USCancer Institute (WIA) · INFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExonuclease 1 (

methodsIn this cohort study with 1,030 consecutive EOC patients, we genotyped four potentially functional polymorphisms in

resultsUsing multivariate Cox proportional hazards regression models, we found that rs851797AG/GG genotypes were significantly associated with recurrence and cancer death (HR =1.30 and 1.38, 95% CI =1.11-1.52 and 1.02-1.88, respectively). Kaplan-Meier survival estimates showed that patients who carried rs851797AG/GG genotypes had poorer progression-free survival and poorer overall survival, compared with rs851797AA genotype carriers (log-rank test,

conclusion

Indexed as

EXO1ovarian cancerpolymorphismprognosis

Identifiers

PMID29042795
PMCPMC5633322
OpenAlexW2760915001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.